Diabetes obesity & metabolism, 1462-8902

Journal

View graph of relations

Related Publications
  1. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study

    Birkeland, K. I., Bodegard, J., Norhammar, A., Kuiper, J. G., Georgiado, E., Beekman-Hendriks, W. L., Thuresson, M., Pignot, M., Herings, R. M. C. & Kooy, A., Apr-2019, In : Diabetes obesity & metabolism. 21, 4, p. 968-974 7 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. What the diabetes data in the FOURIER trial fail to show

    van Bruggen, F. H. & Luijendijk, H. J., Mar-2019, In : Diabetes obesity & metabolism. 21, 3, p. 741-742 2 p.

    Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

  3. An integrative systems biology approach for precision medicine in diabetic kidney disease

    Mulder, S., Hamidi, H., Kretzler, M. & Ju, W., Oct-2018, In : Diabetes obesity & metabolism. 20, p. 6-13 8 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  4. Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers

    Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, M. K., Cain, V. A., Rossing, P., Stefansson, B. V. & Sartipy, P., Mar-2019, In : Diabetes obesity & metabolism. 21, 3, p. 720-725 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis

    Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T. & Perkovic, V., 29-Jan-2019, In : Diabetes obesity & metabolism.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (45) »

ID: 4952827